The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2 : Prognostic-Related Effects in Acute Heart Failure
Martí-Martínez, Arancha (Hospital Clínic Universitari (València))
Núñez, Julio (Hospital Clínic Universitari (València))
López Escribano, Herminio (Hospital Clínic Universitari (València))
Revuelta-López, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mollar, Anna (Hospital Clínic Universitari (València))
Peiró, Marta (Hospital Clínic Universitari (València))
Sanchis, Juan (Hospital Clínic Universitari (València))
Bayés-Genís, Antoni (Universitat Autònoma de Barcelona. Departament de Medicina)
Carratala, Arturo (Hospital Clínic Universitari (València))
Miró, Oscar (Hospital Clínic i Provincial de Barcelona)
Llorens Soriano, Pere (Hospital General Universitario de Alicante (Alacant, País Valencià))
Herrero-Puente, Pablo (Hospital Universitario Central de Asturias)

Data:	2025
Resum:	Background: Acute heart failure (AHF) is a complex syndrome associated with high mortality and hospital readmissions, characterized by volume overload and inflammation. Soluble ST2 (sST2) and antigen carbohydrate 125 (CA125) are emerging biomarkers that reflect these processes and may interact to influence long-term outcomes in AHF patients. This study aims to examine the prognostic relationship between sST2 and CA125 in predicting mortality and heart failure (HF)-related hospitalizations in patients with decompensated heart failure. Methods: In a cohort of 635 patients with AHF, we investigated whether the prognostic value of sST2 varies according to CA125 levels (≤35 vs. >35 U/mL). The endpoints were: (a) time to all-cause death, and (b) the combination of time to death or new HF admission. Results: This study of EAHFE registry data shows that the association between sST2 and long-term adverse outcomes (mortality and HF hospitalizations) in patients with AHF was differentially influenced by CA125 concentrations (p-value for interactions = 0. 031 and 0. 029, respectively). Higher sST2 was associated with the risk of death and the combined risk of death/HF readmission when CA125 was >35 U/mL [HR = 1. 02 (CI 95%: 1. 01-1. 04), p = 0. 006 and 1. 02 (CI 95%: 1. 01-1. 03); p = 0. 013 per increase in 10 ng/mL, respectively], but not when CA125 was ≤35 U/mL. Conclusions: This study highlights the prognostic interaction between sST2 and CA125 in AHF. Elevated sST2 predicts poor outcomes mainly in patients with high CA125 levels (>35 U/mL), suggesting CA125's role in modulating inflammatory activity in HF. Further research is needed.
Ajuts:	Ministerio de Economía y Competitividad 16/11/00420 Ministerio de Economía y Competitividad 16/11/00403 Ministerio de Economía y Competitividad PT13/0002/0031
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Acute heart failure ; CA125 ; sST2 ; Inflammatory modulator
Publicat a:	Biomolecules, Vol. 15, Num. 4 (April 2025) , art. 602, ISSN 2218-273X

DOI: 10.3390/biom15040602
PMID: 40305342

17 p, 3.5 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats